{
  "ticker": "ACLX",
  "company_name": "Arcellx, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05396885",
      "title": "Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Multiple Myeloma",
      "start_date": "2022-07-15",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Kite, A Gilead Company"
    },
    {
      "nct_id": "NCT05457010",
      "title": "Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS",
      "status": "UNKNOWN",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia, Myelodysplastic Syndromes",
      "start_date": "2022-11-28",
      "completion_date": "2025-11-17",
      "enrollment": 0,
      "sponsor": "Arcellx, Inc."
    },
    {
      "nct_id": "NCT06413498",
      "title": "A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Multiple Myeloma",
      "start_date": "2024-08-23",
      "completion_date": "2031-07",
      "enrollment": 0,
      "sponsor": "Kite, A Gilead Company"
    },
    {
      "nct_id": "NCT06626919",
      "title": "A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness",
      "start_date": "2025-04-30",
      "completion_date": "2028-04",
      "enrollment": 0,
      "sponsor": "Arcellx, Inc."
    },
    {
      "nct_id": "NCT04155749",
      "title": "Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Relapsed and Refractory Multiple Myeloma",
      "start_date": "2019-12-23",
      "completion_date": "2026-06",
      "enrollment": 0,
      "sponsor": "Kite, A Gilead Company"
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE2": 1,
      "PHASE1": 3,
      "PHASE3": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "UNKNOWN": 1,
      "RECRUITING": 2
    },
    "active_trials": 4,
    "completed_trials": 0,
    "conditions": [
      "Acute Myeloid Leukemia, Myelodysplastic Syndromes",
      "Multiple Myeloma",
      "Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness",
      "Relapsed and Refractory Multiple Myeloma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:15:58.364508",
    "search_query": "Arcellx, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Arcellx,+Inc."
  }
}